Psychiatry and Neurology, Neurology · Cincinnati, OH
NPI
1417361163
Since 2014
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
3113 Bellevue Ave Fl 3
Cincinnati, OH, 45219
Phone (513) 475-8730
Groups this clinician bills Medicare through
Medicare paid, 2024
$19K
363 services
Medicare patients, 2024
184
Average age 64
Drug cost, 2024
$3.0M
1,971 prescriptions
Company payments, 2025
$103
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Roman M Kassa was code 99213 (office e&m - established), 103 times for 85 patients. In total Roman M Kassa billed 363 services in 10 codes, and Medicare paid $19K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-04-05.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Facility | 103 | 85 | $44.60 | $4,594 |
| 99214 Office E&M - Established | Facility | 101 | 79 | $62.13 | $6,275 |
| 99215 Office E&M - Established | Facility | 75 | 73 | $76.35 | $5,726 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 49 | 49 | $12.04 | $590 |
By year: 2022 $21K for 1,012 services; 2023 $15K for 197 services; 2024 $19K for 363 services.
Medicare prescription drug claims, 2024
In 2024, the drug Roman M Kassa prescribed most often to Medicare patients was Gabapentin, with 221 prescriptions and refills. In total Roman M Kassa wrote 1,971 Medicare prescriptions that cost $3.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 221 | 419 | 66 | $4,821 |
| Baclofen Generic | 164 | 306 | 63 | $3,523 |
| Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine | 132 | 132 | 21 | $3,511 |
| Teriflunomide Generic | 76 | 84 | 13 | $228K |
| Tizanidine Hcl Generic | 64 | 114 | 20 | $665 |
| Duloxetine Hcl Generic | 61 | 114 | 19 | $1,038 |
| Pregabalin Generic | 57 | 101 | 15 | $2,136 |
| Dimethyl Fumarate Generic | 50 | 58 | Under 11 | $10K |
| Clonazepam Generic | 49 | 49 | Under 11 | $104 |
| Trazodone Hcl Generic | 48 | 84 | 14 | $208 |
| Kesimpta Pen Ofatumumab | 44 | 56 | 13 | $483K |
| Amitriptyline Hcl Generic | 44 | 92 | 17 | $391 |
| Glatiramer Acetate Generic | 42 | 42 | Under 11 | $86K |
| Glatopa Glatiramer Acetate | 41 | 41 | Under 11 | $129K |
| Dalfampridine Er Dalfampridine | 41 | 60 | 11 | $20K |
Brand drugs: 241 claims; generic drugs: 1,730 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Roman M Kassa $103 ($103 in general payments such as food, travel and fees) from 4 companies. The largest payer was Vanda Pharmaceuticals Inc. with $39.92.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.